The acquisition of tumor antigen to CER-1236-activated T cells is accompanied by enhanced CER-1236 cross-presentation, as evidenced by the triggering of E7-specific TCR-T responses in a class I and TLR-2-dependent manner. This evidence concerns the gene TLR2 and neoplasm.